72
Participants
Start Date
January 22, 2020
Primary Completion Date
August 19, 2021
Study Completion Date
February 26, 2024
Talimogene laherparepvec
Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
Pembrolizumab
Intravenous (IV) infusion.
Melanoma Institute Australia, North Sydney
Peter MacCallum Cancer Centre, Melbourne
The Alfred Hospital, Melbourne
Tasman Oncology Research, Southport
The Queen Elizabeth Hospital, Woodville South
General Hospital of Athens Laiko, Athens
New York Oncology Hematology, PC, Albany
Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
Onkologikoa, Donostia / San Sebastian
IRCCS Istituto Europeo di Oncologia, Milan
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo
Hospital Universitario La Paz, Madrid
Hospital Universitario Madrid Sanchinarro, Madrid
Hospital Clinico Universitario Virgen de la Victoria, Málaga
Medizinische Hochschule Hannover, Hanover
University of Florida Health Cancer Center at Orlando Health, Orlando
Centre Hospitalier Universitaire de Bordeaux - Hôpital Saint André, Bordeaux
Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon, Grenoble
University of Louisville James Graham Brown Cancer Center, Louisville
Centre Hospitalier Universitaire de Nantes, Hôpital Hôtel Dieu, Nantes
Cleveland Clinic, Cleveland
University Hospital of Ioannina, Ioannina
"IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori", Meldola FC
Allina Health Systems dba Virginia Piper Cancer Institute, Fridley
Centre Hospitalier Lyon Sud, Pierre-Bénite
Universitätsklinikum Tübingen, Tübingen
Hopital Saint Louis, Paris
Baylor Scott and White Research Institute, Dallas
United States Oncology Regulatory Affairs Corporate Office, The Woodlands
Texas Oncology Austin Central, Austin
Universitätsklinikum Regensburg, Regensburg
Sansum Clinic, Santa Barbara
Gustave Roussy, Villejuif
Princess Margaret Cancer Centre, Toronto
Jewish General Hospital, Montreal
CHU de Quebec-Universite Laval, Québec
Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden
Bioclinic of Thessaloniki, Thessaloniki
Nederlands Kanker Instituut, Antoni van Leeuwenhoekziekenhuis, Amsterdam
Erasmus Medisch Centrum, Rotterdam
Uniwersyteckie Centrum Kliniczne Centrum Medycyny Nieinwazyjnej, Gdansk
Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Pozn, Poznan
"Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie †Panstwowy Instytut Badawczy", Warsaw
Hospital Universitari Vall d Hebron, Barcelona
Guys Hospital, London
Royal Marsden Hospital, London
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Amgen
INDUSTRY